Identification of a new series of benzothiazinone derivatives with excellent antitubercular activity and improved pharmacokinetic profiles

Treatment of pulmonary tuberculosis: past and present†

(2017) Dmitry Borisovich Giller et al.   EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY

Tackling Drug-Resistant Tuberculosis: Current Trends and Approaches

(2017) Rashmi Tandon et al.   MINI-REVIEWS IN MEDICINAL CHEMISTRY

Molecular Drug-Susceptibility Test for Tuberculosis

(2017)   NEW ENGLAND JOURNAL OF MEDICINE

From the Viewpoint of Drug Metabolism Research

(2017) Miki Nakajima   YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN

Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents

(2017) Kai Lv et al.   ACS Medicinal Chemistry Letters

DprE1 Is a Vulnerable Tuberculosis Drug Target Due to Its Cell Wall Localization

(2015) Miroslav Brecik et al.   ACS Chemical Biology

The 8-Pyrrole-Benzothiazinones Are Noncovalent Inhibitors of DprE1 from Mycobacterium tuberculosis

(2015) Vadim Makarov et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening

(2015) Ujjini H. Manjunatha et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Tuberculosis

(2014) Yong-Soo Kwon et al.   CURRENT OPINION IN PULMONARY MEDICINE

Towards a new combination therapy for tuberculosis with next generation benzothiazinones

(2014) V. Makarov et al.   EMBO Molecular Medicine

Pharmacokinetics-Pharmacodynamics Analysis of Bicyclic 4-Nitroimidazole Analogs in a Murine Model of Tuberculosis

(2014) Suresh B. Lakshminarayana et al.   PLoS One

Tuberculosis: The drug development pipeline at a glance

(2012) Baptiste Villemagne et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Identification of Antitubercular Benzothiazinone Compounds by Ligand-Based Design

(2012) Tomislav Karoli et al.   JOURNAL OF MEDICINAL CHEMISTRY

Structural basis of inhibition of Mycobacterium tuberculosis DprE1 by benzothiazinone inhibitors

(2012) S. M. Batt et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Pharmacokinetic profile of SKP-1041, a modified release formulation of zaleplon

(2011) David J. Greenblatt et al.   BIOPHARMACEUTICS & DRUG DISPOSITION

Benzothiazinones: Prodrugs That Covalently Modify the Decaprenylphosphoryl-β-d-ribose 2′-epimerase DprE1 ofMycobacterium tuberculosis

(2010) Claudia Trefzer et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Ex vivo permeability experiments in excised rat intestinal tissue and in vitro solubility measurements in aspirated human intestinal fluids support age-dependent oral drug absorption

(2009) Pieter Annaert et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis

(2009) V. Makarov et al.   SCIENCE